by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION Data on how sleep architecture relates to progression of plasma Alzheimer’s disease biomarkers remains limited. METHODS Sixty-four cognitively unimpaired older adults (ages 55–90) underwent plasma collection twice 2.6 years apart and...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION The concentration of endogenous tau microtubule-binding region containing residue-243 in plasma (eMTBR-tau243) has been proposed to be a sensitive biomarker of tangle pathology in Alzheimer’s disease (AD). We assessed eMTBR-tau243 and...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by impaired vascular amyloid-β clearance, distinct from Alzheimer’s disease (AD), underscoring the need to clarify its molecular basis for predicting therapy-related amyloid-related imaging...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract INTRODUCTION Amyloid plaque deposition is a defining feature of Alzheimer’s disease (AD), yet how plaque-associated cellular alterations are reflected in noninvasive imaging remains unclear. METHODS We integrated high-resolution diffusion magnetic...
by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia
Abstract BACKGROUND Farming populations may face a disproportionate share of adverse exposures influencing Alzheimer’s disease (AD), yet farming data are rarely connected to cohorts with characterized AD neuropathology. Whether early-life exposure is related to...
